Não benzodiazepínico (Portuguese Wikipedia)
Analysis of information sources in references of the Wikipedia article "Não benzodiazepínico" in Portuguese language version.
refsWebsite
Global rank
Portuguese rank
710th place
502nd place
low place
4,847th place
5th place
5th place
4,720th place
7,779th place
low place
low place
1,523rd place
3,490th place
1st place
1st place
low place
low place
benzo.org.uk
- Professor Heather Ashton. «Benzodiazepines: How They Work and How to Withdraw»
bmj.com
dtb.bmj.com
- «What's wrong with prescribing hypnotics?». Drug Ther Bull. 42: 89–93. PMID 15587763. doi:10.1136/dtb.2004.421289
consumerreports.org
- «Evaluating Newer Sleeping Pills Used to Treat: Insomnia: Comparing Effectiveness, Safety, and Price» (PDF). Consumer Reports. 1 de janeiro de 2012. p. 14. Consultado em 4 de junho de 2013
doi.org
dx.doi.org
- «What's wrong with prescribing hypnotics?». Drug Ther Bull. 42: 89–93. PMID 15587763. doi:10.1136/dtb.2004.421289
- Wagner J, Wagner ML, Hening WA. «Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia». Ann Pharmacother. 32: 680–91. PMID 9640488. doi:10.1345/aph.17111
- Benca RM. «Diagnosis and treatment of chronic insomnia: a review». Psychiatr Serv. 56: 332–43. PMID 15746509. doi:10.1176/appi.ps.56.3.332
- Neubauer DN (2006). «New approaches in managing chronic insomnia». CNS Spectrums. 11: 1–13. PMID 16871130. doi:10.1017/S1092852900026687
- Najib J (2006). «Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia». Clinical Therapeutics. 28: 491–516. PMID 16750462. doi:10.1016/j.clinthera.2006.04.014
- Lieberman JA (2007). «Update on the Safety Considerations in the Management of Insomnia With Hypnotics: Incorporating Modified-Release Formulations Into Primary Care» (PDF). Primary Care Companion to the Journal of Clinical Psychiatry. 9: 25–31. PMC 1894851
. PMID 17599165. doi:10.4088/pcc.v09n0105 - Kaufmann. «Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010». Pharmacoepidemiology and Drug Safety (em inglês). 25: 637–45. ISSN 1099-1557. PMC 4889508. PMID 26711081. doi:10.1002/pds.3951
- Touitou Y. «[Sleep disorders and hypnotic agents: medical, social and economical impact]». Ann Pharm Fr (em francês). 65: 230–8. PMID 17652991. doi:10.1016/s0003-4509(07)90041-3
- Siriwardena AN, Qureshi MZ, Dyas JV, Middleton H, Orner R. «Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care». Br J Gen Pract. 58: 417–22. PMC 2418994. PMID 18505619. doi:10.3399/bjgp08X299290
- Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (2012). «Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration». BMJ. 345: e8343. PMC 3544552. PMID 23248080. doi:10.1136/bmj.e8343
- Stone JR, Zorick TS, Tsuang J (2007). «Dose-related illusions and hallucinations with zaleplon». Clin Toxicol (Philadelphia). 46: 1–2. PMID 17852167. doi:10.1080/15563650701517442
- Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS (2000). «Central nervous system side effects associated with zolpidem treatment». Clin Neuropharmacol. 23: 54–8. PMID 10682233. doi:10.1097/00002826-200001000-00011
- Yang W, Dollear M, Muthukrishnan SR (2005). «One rare side effect of zolpidem--sleepwalking: a case report». Archives of Physical Medicine and Rehabilitation. 86: 1265–6. PMID 15954071. doi:10.1016/j.apmr.2004.11.022
- Lange CL (2005). «Medication-associated somnambulism». Journal of the American Academy of Child and Adolescent Psychiatry. 44: 211–2. PMID 15725964. doi:10.1097/01.chi.0000150618.67559.48
- Morgenthaler TI, Silber MH (2002). «Amnestic sleep-related eating disorder associated with zolpidem». Sleep Medicine. 3: 323–7. PMID 14592194. doi:10.1016/S1389-9457(02)00007-2
- Liskow B, Pikalov A (2004). «Zaleplon overdose associated with sleepwalking and complex behavior». Journal of the American Academy of Child and Adolescent Psychiatry. 43: 927–8. PMID 15266187. doi:10.1097/01.chi.0000129219.66563.aa
- Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G. «Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety». Int Clin Psychopharmacol. 5: 173–83. PMID 2230061. doi:10.1097/00004850-199007000-00002
- Shader RI, Greenblatt DJ. «Clinical implications of benzodiazepine pharmacokinetics». Am J Psychiatry. 134: 652–6. PMID 17302. doi:10.1176/ajp.134.6.652
- Noyes R, Perry PJ, Crowe RR,; et al. «Seizures following the withdrawal of alprazolam». J. Nerv. Ment. Dis. 174: 50–2. PMID 2867122. doi:10.1097/00005053-198601000-00009
- Menzin J, Lang KM, Levy P, Levy E. «A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France». PharmacoEconomics. 19: 69–78. PMID 11252547. doi:10.2165/00019053-200119010-00005
- Walsh JK. «Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia». Clin Neuropharmacol. 23: 17–21. PMID 10682226. doi:10.1097/00002826-200001000-00004
- Verster JC, Veldhuijzen DS, Volkerts ER. «Residual effects of sleep medication on driving ability». Sleep Med Rev. 8: 309–25. PMID 15233958. doi:10.1016/j.smrv.2004.02.001
- Kripke DF. «Greater incidence of depression with hypnotic use than with placebo». BMC Psychiatry. 7. 42 páginas. PMC 1994947. PMID 17711589. doi:10.1186/1471-244X-7-42
- «Mortality Risk of Hypnotics: Strengths and Limits of Evidence.» (PDF). Drug Safety. 39: 93–107. PMID 26563222. doi:10.1007/s40264-015-0362-0
- «Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis.». Age and Ageing. 47: 201–208. PMID 29077902. doi:10.1093/ageing/afx167
- Barbera J, Shapiro C (2005). «Benefit-risk assessment of zaleplon in the treatment of insomnia». Drug Saf. 28: 301–18. PMID 15783240. doi:10.2165/00002018-200528040-00003
- Mets MA, Volkerts ER, Olivier B, Verster JC. «Effect of hypnotic drugs on body balance and standing steadiness». Sleep Med Rev. 14: 259–67. PMID 20171127. doi:10.1016/j.smrv.2009.10.008
- Antai-Otong D. «The art of prescribing. Risks and benefits of non-benzodiazepine receptor agonists in the treatment of acute primary insomnia in older adults». Perspect Psychiatr Care. 42: 196–200. PMID 16916422. doi:10.1111/j.1744-6163.2006.00070.x
- «What's wrong with prescribing hypnotics?». Drug Ther Bull. 42: 89–93. PMID 15587763. doi:10.1136/dtb.2004.421289
- Quaglio G, Lugoboni F, Fornasiero A, Lechi A, Gerra G, Mezzelani P. «Dependence on zolpidem: two case reports of detoxification with flumazenil infusion». Int Clin Psychopharmacol. 20: 285–7. PMID 16096519. doi:10.1097/01.yic.0000166404.41850.b4
- Kripke DF (15 de dezembro de 2015). «Who Should Sponsor Sleep Disorders Pharmaceutical Trials?». J Clin Sleep Med. 3 (7): 671–3. PMC 2556906. PMID 18198797. doi:10.5664/jcsm.27020.
major hypnotic trials is needed to more carefully study potential adverse effects of hypnotics such as daytime impairment, infection, cancer, and death and the resultant balance of benefits and risks.
escholarship.org
- «Mortality Risk of Hypnotics: Strengths and Limits of Evidence.» (PDF). Drug Safety. 39: 93–107. PMID 26563222. doi:10.1007/s40264-015-0362-0
nih.gov
ncbi.nlm.nih.gov
- «What's wrong with prescribing hypnotics?». Drug Ther Bull. 42: 89–93. PMID 15587763. doi:10.1136/dtb.2004.421289
- Siriwardena AN, Qureshi Z, Gibson S, Collier S, Latham M. «GPs' attitudes to benzodiazepine and 'Z-drug' prescribing: a barrier to implementation of evidence and guidance on hypnotics». Br J Gen Pract. 56: 964–7. PMC 1934058. PMID 17132386
- Wagner J, Wagner ML, Hening WA. «Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia». Ann Pharmacother. 32: 680–91. PMID 9640488. doi:10.1345/aph.17111
- Benca RM. «Diagnosis and treatment of chronic insomnia: a review». Psychiatr Serv. 56: 332–43. PMID 15746509. doi:10.1176/appi.ps.56.3.332
- Lader MH. «Implications of hypnotic flexibility on patterns of clinical use». Int J Clin Pract Suppl: 14–9. PMID 11219327
- Neubauer DN (2006). «New approaches in managing chronic insomnia». CNS Spectrums. 11: 1–13. PMID 16871130. doi:10.1017/S1092852900026687
- Najib J (2006). «Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia». Clinical Therapeutics. 28: 491–516. PMID 16750462. doi:10.1016/j.clinthera.2006.04.014
- Lieberman JA (2007). «Update on the Safety Considerations in the Management of Insomnia With Hypnotics: Incorporating Modified-Release Formulations Into Primary Care» (PDF). Primary Care Companion to the Journal of Clinical Psychiatry. 9: 25–31. PMC 1894851. PMID 17599165. doi:10.4088/pcc.v09n0105
- Kaufmann. «Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010». Pharmacoepidemiology and Drug Safety (em inglês). 25: 637–45. ISSN 1099-1557. PMC 4889508. PMID 26711081. doi:10.1002/pds.3951
- Touitou Y. «[Sleep disorders and hypnotic agents: medical, social and economical impact]». Ann Pharm Fr (em francês). 65: 230–8. PMID 17652991. doi:10.1016/s0003-4509(07)90041-3
- Siriwardena AN, Qureshi MZ, Dyas JV, Middleton H, Orner R. «Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care». Br J Gen Pract. 58: 417–22. PMC 2418994. PMID 18505619. doi:10.3399/bjgp08X299290
- Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (2012). «Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration». BMJ. 345: e8343. PMC 3544552. PMID 23248080. doi:10.1136/bmj.e8343
- Stone JR, Zorick TS, Tsuang J (2007). «Dose-related illusions and hallucinations with zaleplon». Clin Toxicol (Philadelphia). 46: 1–2. PMID 17852167. doi:10.1080/15563650701517442
- Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS (2000). «Central nervous system side effects associated with zolpidem treatment». Clin Neuropharmacol. 23: 54–8. PMID 10682233. doi:10.1097/00002826-200001000-00011
- Mellingsaeter TC, Bramness JG, Slørdal L (2006). «[Are z-hypnotics better and safer sleeping pills than benzodiazepines?]». Tidsskrift for den Norske Laegeforening (em norueguês). 126: 2954–6. PMID 17117195
- Yang W, Dollear M, Muthukrishnan SR (2005). «One rare side effect of zolpidem--sleepwalking: a case report». Archives of Physical Medicine and Rehabilitation. 86: 1265–6. PMID 15954071. doi:10.1016/j.apmr.2004.11.022
- Lange CL (2005). «Medication-associated somnambulism». Journal of the American Academy of Child and Adolescent Psychiatry. 44: 211–2. PMID 15725964. doi:10.1097/01.chi.0000150618.67559.48
- Morgenthaler TI, Silber MH (2002). «Amnestic sleep-related eating disorder associated with zolpidem». Sleep Medicine. 3: 323–7. PMID 14592194. doi:10.1016/S1389-9457(02)00007-2
- Liskow B, Pikalov A (2004). «Zaleplon overdose associated with sleepwalking and complex behavior». Journal of the American Academy of Child and Adolescent Psychiatry. 43: 927–8. PMID 15266187. doi:10.1097/01.chi.0000129219.66563.aa
- Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G. «Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety». Int Clin Psychopharmacol. 5: 173–83. PMID 2230061. doi:10.1097/00004850-199007000-00002
- Shader RI, Greenblatt DJ. «Clinical implications of benzodiazepine pharmacokinetics». Am J Psychiatry. 134: 652–6. PMID 17302. doi:10.1176/ajp.134.6.652
- Noyes R, Perry PJ, Crowe RR,; et al. «Seizures following the withdrawal of alprazolam». J. Nerv. Ment. Dis. 174: 50–2. PMID 2867122. doi:10.1097/00005053-198601000-00009
- Menzin J, Lang KM, Levy P, Levy E. «A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France». PharmacoEconomics. 19: 69–78. PMID 11252547. doi:10.2165/00019053-200119010-00005
- Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A. «Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol». Sleep. 25: 224–31. PMID 11905433
- Walsh JK. «Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia». Clin Neuropharmacol. 23: 17–21. PMID 10682226. doi:10.1097/00002826-200001000-00004
- Verster JC, Veldhuijzen DS, Volkerts ER. «Residual effects of sleep medication on driving ability». Sleep Med Rev. 8: 309–25. PMID 15233958. doi:10.1016/j.smrv.2004.02.001
- Kripke DF. «Greater incidence of depression with hypnotic use than with placebo». BMC Psychiatry. 7. 42 páginas. PMC 1994947. PMID 17711589. doi:10.1186/1471-244X-7-42
- «Mortality Risk of Hypnotics: Strengths and Limits of Evidence.» (PDF). Drug Safety. 39: 93–107. PMID 26563222. doi:10.1007/s40264-015-0362-0
- «Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis.». Age and Ageing. 47: 201–208. PMID 29077902. doi:10.1093/ageing/afx167
- Barbera J, Shapiro C (2005). «Benefit-risk assessment of zaleplon in the treatment of insomnia». Drug Saf. 28: 301–18. PMID 15783240. doi:10.2165/00002018-200528040-00003
- Mets MA, Volkerts ER, Olivier B, Verster JC. «Effect of hypnotic drugs on body balance and standing steadiness». Sleep Med Rev. 14: 259–67. PMID 20171127. doi:10.1016/j.smrv.2009.10.008
- Antai-Otong D. «The art of prescribing. Risks and benefits of non-benzodiazepine receptor agonists in the treatment of acute primary insomnia in older adults». Perspect Psychiatr Care. 42: 196–200. PMID 16916422. doi:10.1111/j.1744-6163.2006.00070.x
- «What's wrong with prescribing hypnotics?». Drug Ther Bull. 42: 89–93. PMID 15587763. doi:10.1136/dtb.2004.421289
- Quaglio G, Lugoboni F, Fornasiero A, Lechi A, Gerra G, Mezzelani P. «Dependence on zolpidem: two case reports of detoxification with flumazenil infusion». Int Clin Psychopharmacol. 20: 285–7. PMID 16096519. doi:10.1097/01.yic.0000166404.41850.b4
- Kripke DF (15 de dezembro de 2015). «Who Should Sponsor Sleep Disorders Pharmaceutical Trials?». J Clin Sleep Med. 3 (7): 671–3. PMC 2556906. PMID 18198797. doi:10.5664/jcsm.27020.
major hypnotic trials is needed to more carefully study potential adverse effects of hypnotics such as daytime impairment, infection, cancer, and death and the resultant balance of benefits and risks.
nlm.nih.gov
- MedlinePlus (8 de janeiro de 2001). «Eszopiclone». National Institutes of Health. Consultado em 21 de abril de 2008. Cópia arquivada em 27 de fevereiro de 2008
oxforddictionaries.com
- «benzodiazepine - definition of benzodiazepine in English from the Oxford dictionary». OxfordDictionaries.com. Consultado em 20 de janeiro de 2016
psychiatrist.com
- Lieberman JA (2007). «Update on the Safety Considerations in the Management of Insomnia With Hypnotics: Incorporating Modified-Release Formulations Into Primary Care» (PDF). Primary Care Companion to the Journal of Clinical Psychiatry. 9: 25–31. PMC 1894851. PMID 17599165. doi:10.4088/pcc.v09n0105
tidsskriftet.no
- Mellingsaeter TC, Bramness JG, Slørdal L (2006). «[Are z-hypnotics better and safer sleeping pills than benzodiazepines?]». Tidsskrift for den Norske Laegeforening (em norueguês). 126: 2954–6. PMID 17117195
web.archive.org
- MedlinePlus (8 de janeiro de 2001). «Eszopiclone». National Institutes of Health. Consultado em 21 de abril de 2008. Cópia arquivada em 27 de fevereiro de 2008
wiley.com
www3.interscience.wiley.com
- Antai-Otong D. «The art of prescribing. Risks and benefits of non-benzodiazepine receptor agonists in the treatment of acute primary insomnia in older adults». Perspect Psychiatr Care. 42: 196–200. PMID 16916422. doi:10.1111/j.1744-6163.2006.00070.x
worldcat.org
- Kaufmann. «Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010». Pharmacoepidemiology and Drug Safety (em inglês). 25: 637–45. ISSN 1099-1557. PMC 4889508. PMID 26711081. doi:10.1002/pds.3951